When was Sebia founded?

Sebia was founded in 1967 and raised its 1st funding round 34 years after it was founded.

Where is Sebia located?

Sebia is headquartered in Evry Courcouronnes, France. It is registered at Norcross, Georgia.

How many employees does Sebia have?

As of May 31, 2026, the latest employee count at Sebia is 1004.

Is Sebia a funded company?

Sebia is a funded company, having raised an undisclosed amount across 6 funding rounds to date. The company's 1st funding round was a $***** PE round, raised on 2001.

When was the latest funding round of Sebia?

Sebia's latest funding was a $***** Grant (prize money) round on Jan 01, 2023, with participation from 1 investor.

What is the annual revenue of Sebia?

Annual revenue of Sebia is £12.8M as on Dec 31, 2024.

Where does Sebia rank among its competitors?

Sebia ranks 10th amongst 474 active competitors, of which 60 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was RareCyte, which secured $658K in May, 2025.

Who are the top competitors of Sebia?

Sebia's top competitors include Enzo, Sino Biological and Qiagen. Among them, RareCyte secured the most recent funding round in May, 2025.

Sebia - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of electrophoresis-based in vitro diagnostics products. It provides technology solutions for both capillary and gel electrophoresis, along with bundled software packages, and a test menu for diabetes, hematological disorders, multiple myeloma, and alcoholism.

Website: www.sebia.com/
Registered Address: Norcross, Georgia

Key Metrics

Founded Year

1967

Location

Evry Courcouronnes, France

Stage

Acquired

Latest Funding Round

Grant (prize money), Jan 01, 2023, $*****

Investors

Astorg Partners & 5 more

Ranked

10^th among 474 active competitors

Annual Revenue

£12.8M as on Dec 31, 2024

Employee Count

1,004 as on May 31, 2026

Investment & Acquisitions

ZEUS Scientific & 1 more

Similar Companies

Qiagen & 303 more

Exit Details

Acquired by CVC (Oct 12, 2017)

View Sebia's full profile

Sebia is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
SEBIA, INC CIN: 582350735 , United States, Active	Dec 26, 999	-	193 (As on Dec 31, 2024)	-
Sabia Solutions s.r.o. CIN: 01916033 , Czech Republic, Active	Jul 22, 2013	-	-
SEBIA (UK) LTD CIN: 5758364 , United Kingdom, Active	Mar 26, 2006	$16.4M (As on Dec 31, 2024)	28 (As on Dec 31, 2024)
SEBIA DIAGNOSTICS INDIA PRIVATE LIMITED CIN: U85110HR2019FTC083840 , India, Active	Nov 26, 2019	$7.6M (As on Mar 31, 2025)	-

Sebia got acquired by CVC and Tethys Investments on Oct 12, 2017 at an acquisition amount of $*****.

Click here to take a look at Sebia's acquisition in detail

Sebia has raised funding over 6 rounds. Its first funding round was on 2001. Its latest funding round was a Grant (prize money) round on Jan 01, 2023 for $*****. 1 investor participated in its latest round. Sebia has 6 institutional investors.

Here is the list of recent funding rounds of Sebia:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 01, 2023	6184768	Grant (prize money)	5870496	1125759	7269001	5724778
Dec 14, 2016	6055022	Grant (prize money)	3745555	3497514	9328100	Europa
2015	4622	Grant (prize money)	5916	5886	8817	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Sebia's funding rounds and investors

Sebia's employee count trend

Sebia has 1,004 employees as of May 26. Here is Sebia's employee count trend over the years:

Uncover Sebia's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sebia include Enzo, Sino Biological and Qiagen. Here is the list of Top 10 competitors of Sebia, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Enzo 1976, Farmingdale (United States), Acquired	Life science products and services for research, drug discovery, and manufacturing	$7M	-	67/100
2nd	Sino Biological 2007, Beijing (China), Series A	Provider of reagents,and kits for clinical research	$29.4M	Qiming Venture Partners, CTS Capital & 1 others	67/100
3rd	Qiagen 1984, Venlo (Netherlands), Acquired	Provider of products and reagents for molecular diagnostic assays	-	Life Sciences Partners, EQT & 5 others	64/100
4th	Parse Biosciences 2018, Seattle (United States), Series C	Developer of RNA-sequencing solution-based transcriptome kit to analyze health data	$100M	Janus Henderson Investors, Marshall Wace & 7 others	64/100
5th	Devyser 2004, Stockholm (Sweden), Public	Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders	$15.5M	Swedbank Robur, Fjarde AP-fonden & 1 others	61/100
6th	Miltenyi Biotec 1989, Bergisch Gladbach (Germany), Funding Raised	Develops tools and products for research and clinical application	-	Europa, HHS	59/100
7th	RareCyte 2009, Seattle (United States), Series C	Developer of technologies for the analysis of rare and single cells in the blood	$114M	Arboretum Ventures, Health Quest Capital ... & 11 others	57/100
8th	Neogen 1982, Lansing (United States), Acquired	Solutions for food and animal safety, diagnostics, and genomics	$700K	Innovative Ventures, NISA	57/100
9th	Constructive Bio 2022, Saffron Walden (United Kingdom), Series A	Provider of a platform for genome and polymer synthesis	$75M	Ahren, OMX Ventures & 9 others	56/100
10th	Sebia 1967, Evry Courcouronnes (France), Acquired	Developer of electrophoresis-based in vitro diagnostics products	-	Astorg Partners, AlpInvest Partners & 4 others	56/100